Join our newsletter
Get updated info, tips and news about breastfeeding, e-lactancia project and other initiatives from APILAM
Legitimation: Consent of the interested party
As a user and interested I inform you that the data you provide will be located on the servers of MailChimp (email marketing provider of APILAM) outside the EU in the USA. MailChimp is covered by the EU-US Privacy Shield agreement, whose information is available here, approved by the European Committee for Data Protection. See Mailchimp's privacy policy. (https://mailchimp.com/legal/privacy/).
The fact that you do not enter the personal data that appear on the form as mandatory may have the consequence that we can not meet your request.
You can exercise your rights of access, rectification, limitation and delete the data in apilam.es@gmail.com as well as the right to file a claim with a control authority.
You can consult the additional and detailed information on Data Protection on this website: http://e-lactancia.org, as well as consult our own privacy policy.
A non-steroidal anti-inflammatory drug with analgesic properties belonging to the oxicam group. Indicated for the short-term relief of mild to moderate acute pain. Administered orally in one or two daily doses.
As of the last update, we found no published data on its excretion in breast milk.
Its high plasma protein binding makes it highly unlikely to pass into breast milk. Another drug from the same group with the same degree of protein binding, Piroxicam, has negligible excretion in breast milk. Lornoxicam is the only one in the group with the shortest half-life.
Until further data on this drug becomes available, known safer alternatives may be preferable, particularly when breastfeeding newborns under one month old or premature infants.
See below the information of this related product: